Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 7/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17297122 | 0.85 | PAOX (0.48) | PAOXADRA1AKDM4EMAPK1HIF1A | |
| SCHEMBL10301546 | 0.85 | PAOX (0.48) | PAOXADRA1AKDM4EMAPK1HIF1A | |
| SCHEMBL16401715 | 0.83 | PRMT1 (0.59) | ADRA1AMAPK1PLA2G2APRMT1EPHX2 | |
| SCHEMBL9137891 | 0.82 | PAOX (0.46) | PAOXADRA1AKDM4EMAPK1HIF1A | |
| SCHEMBL20210381 | 0.82 | NAMPT (0.43) | ADRA1AKDM4EMAPK1HIF1APLA2G2A | |
| SCHEMBL16401714 | 0.82 | EPHX2 (0.48) | PLA2G2AEPHX2 | |
| SCHEMBL16283424 | 0.81 | PLA2G2A (0.38) | ADRA1AKDM4EMAPK1HIF1APLA2G2A | |
| SCHEMBL18327189 | 0.80 | PLA2G2A (0.41) | ADRA1AKDM4EMAPK1HIF1APLA2G2A | |
| SCHEMBL15259290 | 0.79 | ADRA1A (0.53) | PAOXADRA1AKDM4EMAPK1HIF1A | |
| SCHEMBL18769692 | 0.76 | KDM4E (0.39) | PAOXADRA1AKDM4EMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140363454-A1 | Antibody-Drug Conjugates, Compositions and Methods of Use | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363454-A1 | Antibody-Drug Conjugates, Compositions and Methods of Use | SDCBP, CD81, DSTN | PAOX 4498/4885ADRA1A 4205/4885KDM4E 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.